Positive topline results from Clarity’s PROPELLER SAR-bisPSMA prostate cancer diagnostic trial
Sydney, Australia 14 December 2022 Highlights Clarity’s diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER meets all primary and secondary objectives 64Cu SAR-bisPSMA is safe and well tolerated in trial participants 64Cu SAR-bisPSMA is shown to be efficacious in the detection of primary prostate cancer A dose of 200 megabecquerels (MBq) of 64Cu SAR-bisPSMA was determined…